Neurocrine Biosciences Chief Legal Officer Reports PRSU Vesting & Tax Withholding
NEUROCRINE BIOSCIENCES INC
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 4 Filing Alert: NEUROCRINE BIOSCIENCES INC ($NBIX) š¤ Insider: Darin Lippoldt (Chief Legal Officer) š Transaction Date: September 11, 2026
Transaction Breakdown: ā¢ PRSU Vesting: Acquired 4,483 shares ($0.00) ā¢ Tax Withholding (Code F): Disposed 2,419 shares @ $156.22 (~$377,896.18) ā¢ Net Addition: +2,064 shares ā¢ Direct Post-Transaction Holdings: 56,793 shares
š Trading Significance: Low (Routine performance RSU vesting and automatic tax withholding)
Comprehensive Analysis
Executive Summary
On September 15, 2026, Neurocrine Biosciences, Inc. ($NBIX) filed a Form 4 on behalf of Darin Lippoldt, the company's Chief Legal Officer. The filing reports equity transactions executed on September 11, 2026, resulting from the vesting of performance restricted stock units (PRSUs) and associated tax withholding.
Transaction Summary
-
Performance Unit Vesting (Code A):
- Shares Acquired: 4,483 common shares
- Price: $0.00 (Achievement of performance metrics certified on September 11, 2026)
-
Tax Withholding (Code F):
- Shares Withheld: 2,419 common shares
- Price Per Share: $156.22
- Total Value Withheld: $377,896.18
- Purpose: Non-discretionary share surrender to cover tax liabilities upon PRSU vesting
Net Impact on Holdings
- Net Share Increase: +2,064 shares
- Post-Transaction Direct Holdings: 56,793 common shares
Significance
This filing carries Low trading significance. The disposition of shares was an automatic tax withholding event (Code F) following the certification of PRSU performance milestones rather than an open-market insider sale.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.